These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35800783)

  • 21. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
    Mensa FJ; Lovell S; Pilot-Matias T; Liu W
    Future Microbiol; 2019 Jan; 14():89-110. PubMed ID: 30499343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
    Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV
    Hepatology; 2020 Jul; 72(1):7-18. PubMed ID: 31652357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
    Kaba A; Yamanaga S; Hidaka Y; Toyoda M; Kashima M; Takekuma Y; Inadome A; Yokomizo H; Miyata A
    Transplant Proc; 2022 Mar; 54(2):549-551. PubMed ID: 35120765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
    Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
    J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.
    Morishita A; Ogawa C; Moriya A; Tani J; Yoneyama H; Fujita K; Oryu M; Senoo T; Takaguchi K; Masaki T
    Hepatol Res; 2020 May; 50(5):557-564. PubMed ID: 31883211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
    Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ
    N Engl J Med; 2018 Jan; 378(4):354-369. PubMed ID: 29365309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
    Kosloski MP; Zhao W; Marbury TC; Preston RA; Collins MG; Pugatch D; Mensa F; Kort J; Liu W
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world.
    Tamori A; Inoue K; Kagawa T; Takaguchi K; Nouso K; Iwasaki Y; Minami M; Hai H; Enomoto M; Kawada N
    Hepatol Res; 2019 Dec; 49(12):1365-1373. PubMed ID: 31323165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report.
    Onodera K; Onishi Y; Inoue J; Tanaka Y; Yonha L; Ichikawa S; Fukuhara N; Yokoyama H; Murai K; Masamune A; Harigae H
    J Infect Chemother; 2021 Aug; 27(8):1230-1233. PubMed ID: 33589371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
    D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir.
    Totsuka M; Honda M; Kanda T; Ishii T; Matsumoto N; Yamana Y; Kaneko T; Mizutani T; Takahashi H; Kumagawa M; Sasaki R; Masuzaki R; Kanezawa S; Nirei K; Yamagami H; Matsuoka S; Ohnishi H; Okamoto H; Moriyama M
    Intern Med; 2021 Jul; 60(13):2061-2066. PubMed ID: 33518580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2019 Jan; 91(1):102-106. PubMed ID: 30091810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC
    Gastroenterol Hepatol (N Y); 2017 Dec; 13(12 Suppl 5):1-24. PubMed ID: 29950953
    [No Abstract]   [Full Text] [Related]  

  • 39. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection.
    Hammami MB; Aboushaar R; Alsabbagh E
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31129632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.